Real-World Eculizumab Dosing Patterns Among Patients with Paroxysmal Nocturnal Hemoglobinuria in a US Population

PURPOSE: Current pharmacologic management of paroxysmal nocturnal hemoglobinuria (PNH) consists of C5 inhibitors, eculizumab and ravulizumab; however, because patients experience incomplete symptom control, off-label doses may be utilized. We conducted a retrospective, longitudinal cohort study of p...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Wendy Y, Sarda, Sujata P, Mody-Patel, Nikita, Krishnan, Sangeeta, Yenikomshian, Mihran, Kunzweiler, Colin, Vu, Jensen Duy, Cheung, Hoi Ching, Duh, Mei Sheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9078865/
https://www.ncbi.nlm.nih.gov/pubmed/35535299
http://dx.doi.org/10.2147/CEOR.S346816

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9078865/
https://www.ncbi.nlm.nih.gov/pubmed/35535299
http://dx.doi.org/10.2147/CEOR.S346816

Ejemplares similares